[Effect of thymalin on immunologic reactivity of patients with non-specific lung diseases].
Dovnar. T E TE; Mikhaĭlova. N A NA; Khavinson. V Kh VKh
Key Findings
- Thymalin increased overall lymphocyte count and normalized CD4+/CD8+ ratios
- No significant changes in leukocyte chemotaxis, phagocytosis, immunoglobulin levels, or immune complexes
- Patients with intact phagocytic function showed a clearer clinical benefit
Practical Outcomes
- Thymalin may be useful as a short‑term immune‑boosting supplement, especially for supporting T‑cell balance, but it doesn’t broadly enhance all immune functions. The study’s tiny size and specific patient group mean it’s not a proven longevity hack yet, and anyone considering it should start with the low‑dose regimen used (5 ml, 4‑6 injections per course) and monitor effects closely.
Summary
A small study gave 21 people with vague lung problems a peptide called thymalin (5 ml per dose, 4‑6 injections per treatment) and saw their immune cells improve, especially the balance of helper and suppressor T‑cells, while other immune measures stayed the same. The treatment also helped the disease run better in those whose phagocytic (cell‑eating) system was still working.
Abstract
A total of 35 patients with non-specific pulmonary diseases were examined. Twenty-one patients were administered thymalin in addition to standard treatment. Fourteen subjects made up a control group. Immunologic studies made it possible to establish that administration of thymalin in relatively small doses (5 ml, 4-6 injections per treatment course) is an effective means of correcting the decreased characteristics of cellular immunity, favouring the normalization of the lymphocyte count and of the proportion of OKT-4+ and OKT-8+ subpopulations. The drug was found to exert no substantial effect on the other characteristics of immunity, namely on chemotaxis and phagocytosis of leukocytes, the content of immunoglobulins and on circulating immune complexes. Thymalin produced an appreciably beneficial action on the disease course in patients with preserved function of the phagocytic component.
Study Information
pubmed
1989